The estimated Net Worth of James N Wilson is at least $12 Million dollars as of 14 June 2022. Mr. Wilson owns over 300,000 units of Corcept Therapeutics Inc stock worth over $10,665,000 and over the last 21 years he sold CORT stock worth over $718,800. In addition, he makes $631,061 as Independent Chairman of the Board at Corcept Therapeutics Inc.
James has made over 35 trades of the Corcept Therapeutics Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently he exercised 300,000 units of CORT stock worth $624,000 on 14 June 2022.
The largest trade he's ever made was buying 360,000 units of Corcept Therapeutics Inc stock on 30 March 2007 worth over $360,000. On average, James trades about 36,176 units every 96 days since 2004. As of 14 June 2022 he still owns at least 300,000 units of Corcept Therapeutics Inc stock.
You can see the complete history of Mr. Wilson stock trades at the bottom of the page.
James N. Wilson serves as Independent Chairman of the Board of the Company. From 2005 to 2018, he was also a member of the board of directors of NuGEN Technologies, Inc. (“NuGEN”), a provider of systems for genomic analysis. From 2002 to 2009, Mr. Wilson served as the lead independent director of Amylin Pharmaceuticals, Inc. (“Amylin”), a publicly-traded biopharmaceutical company, and from 1996 to 2001, he was Chairman of the board of directors of Amira Medical, Inc., which was acquired by Hoffmann-La Roche A.G. From 1991 to 1994, Mr. Wilson was Chief Operating Officer of Syntex Corporation (“Syntex”), which was acquired by Roche Holding, Ltd. From 1989 to 1990, Mr. Wilson was Chairman and Chief Executive Officer of Neurex Corporation (“Neurex”), which was acquired by Elan Corporation plc. From 1982 to 1988, he was Chief Executive Officer of LifeScan, Inc., which was acquired by Johnson & Johnson Company. Mr. Wilson received his B.A. and M.B.A. from the University of Arizona.
As the Independent Chairman of the Board of Corcept Therapeutics Inc, the total compensation of James Wilson at Corcept Therapeutics Inc is $631,061. There are 9 executives at Corcept Therapeutics Inc getting paid more, with Joseph Belanoff having the highest compensation of $4,958,970.
James Wilson is 76, he's been the Independent Chairman of the Board of Corcept Therapeutics Inc since 2016. There are 1 older and 17 younger executives at Corcept Therapeutics Inc. The oldest executive at Corcept Therapeutics Inc is George Baker, 77, who is the Independent Director.
James's mailing address filed with the SEC is C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK, CA, 94025.
Over the last 21 years, insiders at Corcept Therapeutics Inc have traded over $107,318,493 worth of Corcept Therapeutics Inc stock and bought 71,912,273 units worth $127,133,071 . The most active insiders traders include Patrick G Enright, Allen Andersson und Ventures, Llc Paperboy. On average, Corcept Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $8,010,233. The most recent stock trade was executed by William Guyer on 3 September 2024, trading 10,000 units of CORT stock currently worth $216,500.
leading the field in the discovery of drugs that modulate the effects of cortisol the adverse effects of excess cortisol have been corcept’s focus since the company’s inception. abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol. in addition to our work with mifepristone, we have developed over 300 proprietary molecules, advancing the most promising of these to the clinic to see if they can mitigate the effects of excess cortisol and the serious, sometimes life-threatening conditions that may result. all of these compounds competitively block the glucocorticoid receptor (gr), but not the progesterone receptor. scientific literature suggests that competitive gr antagonism may have a role in treating many conditions, including post-traumatic stress disorder, mild cognitive impairment, alzheimer’s disease, alcoholis
Corcept Therapeutics Inc executives and other stock owners filed with the SEC include: